Effects of Incretin Mimetic Drugs on Diabetic Cardiovascular Functions

Because GLP-1 plays more effective role than GIP in the incretin effect, two drug groups have been developed for treatment of diabetes, in order to enhance GLP-1 concentration in the gastrointestinal system. Clinical studies have shown that they reduce HbA1c levels by 0.5%-1% (Jayawardene et al., 20...

Full description

Saved in:
Bibliographic Details
Published inFABAD journal of pharmaceutical sciences Vol. 42; no. 2; p. 151
Main Authors Boztaş, Ceren Uyar, Inan, Ebru Arioğlu, Altan, Vecdi Melih
Format Journal Article
LanguageEnglish
Published Ankara Hacettepe University Faculty of Medicine 01.04.2017
Subjects
Acute coronary syndromes
Apoptosis
Cardiovascular disease
Diabetes
Drugs
Glucose
Homeostasis
Insulin
Kinases
Mortality
Oxidative stress
Peptides
Rodents
Studies
Online AccessGet full text

Cover

More Information
Summary:Because GLP-1 plays more effective role than GIP in the incretin effect, two drug groups have been developed for treatment of diabetes, in order to enhance GLP-1 concentration in the gastrointestinal system. Clinical studies have shown that they reduce HbA1c levels by 0.5%-1% (Jayawardene et al., 2014; Jose & Inzucchi, 2012). Because they cannot increase blood GLP-1 level as GLP-1 receptor agonists (Waldrop et al., 2016), they cannot slow down gastric emptying time, and their effect on body weight is neutral. [...]DPP-4 inhibitors except alogliptin and saxagliptin do not increase the risk of heart failure or incidence of major adverse cardiovascular events. [...]animal studies using DPP-4 inhibitors in non-diabetic animals have shown that DPP-4 inhibitors displayed a pleotropic effect and contributed in improvement of left ventricular functions that were disturbed because of ischemia/reperfusion injury, and reduced infarction size (Huisamen, Genis, Marais, & Lochner, 2011; Sauve et al., 2010).
ISSN:1300-4182